Risperdal Plaintiffs Gain Leverage in Wake of $70M Verdict

Friday, July 8, 2016

Jim Heller, chair of Cozen O'Connor's Products Liability practice, discusses the Risperdal mass tort in the Legal Intelligencer. A Philadelphia jury on July 1 returned the award against Janssen and in favor of a boy who claimed the antipsychotic drug, Risperdal, led to excess growth of breast tissue. The plaintiffs in A.Y. v. Janssen Pharmaceuticals had argued that the company knew the medication caused the condition but failed to properly inform the medical community, emphasizing potential profits for the drug over its safety. Attorneys noted that an appeal is coming, and several questioned whether the full amount will survive a remittitur challenge. "I'd rather be the appellee than appellant ... but I don't see how they can substantiate a verdict for those damages," said Jim.

To read the article, click here.


James H. Heller

Co-Chair, Commercial Litigation Department
Chair, Product Liability


(215) 665-2189


Related Practice Areas

Keep up-to-date with the latest news from Cozen O'Connor

Enter your City or Zip.

Probably shouldn't change this:
Sign up to receive alerts, publications, and event / webinar invites.

By submitting your contact information, you are giving Cozen O'Connor consent to contact you via email.